GP

Gary Phillips

Pharmaxis Ltd | Chief Executive Officer, Managing Director
Mr Phillips has more than 30 years of operational management experience in the pharmaceutical and healthcare industry in Europe, Asia and Australia. From 1994 to 1998, he was Chief Executive Officer at Ciba Geigy in Hungary (Merged to form Novartis in 1996) where he led the launch of a portfolio of new products. After a period of three years as an Area Manager for Novartis responsible for 9 countries in Asia Pacific in 2001 he joined Novartis Australia as Group Company Head and Chief Executive Officer of its Pharmaceutical Division, launching leading oncology and ophthalmology products.

Companies and Roles

Company
Title
Tenure
Since
PXS
PXS
Pharmaxis Ltd
  • Chief Executive Officer
  • Managing Director
12yrs, 1mthMar 2013
SNT
SNT
Syntara Limited
  • Chief Executive Officer
  • Managing Director
12yrs, 1mthMar 2013
ALA
ALA
Arovella Therapeutics Limited
  • Non-Executive Director
2yrs, 9mthJul 2022

Holdings

Company
Last Notice
Direct Shares
Indirect Shares
Options
Convertibles
SNT
SNT
Syntara Limited
29/11/245,699,8435,369,1049,616,800N/A
ALA
ALA
Arovella Therapeutics Limited
26/11/240788,8882,572,000N/A
PXS
PXS
Pharmaxis Ltd
29/11/235,699,8435,369,1046,845,800N/A

Transactions

Company
Date
Type
Amount
Price
Value
Notes
SNT
SNT
Syntara Limited
29/11/24
Issued
2,771,000$0.056$155,176Issue of options
ALA
ALA
Arovella Therapeutics Limited
26/11/24
Issued
354,000$0.185$65,490Director remuneration
ALA
ALA
Arovella Therapeutics Limited
28/03/24
Buy
66,666$0.150$10,000On-market trade
ALA
ALA
Arovella Therapeutics Limited
04/12/23
Issued
618,000$0.088$54,384Director remuneration
PXS
PXS
Pharmaxis Ltd
29/11/23
Issued
2,771,000$0.030$83,130Issue of options